- Round ID
- FR-00546
- Stage
- Series B
- Round name
- Series B
- Amount
- £80M / $105M
Dated funding evidence
Purespring Therapeutics
Series B · £80M / $105M · 2024-10-01
Reported round£80M / $105MSeries B
- Disclosure date
- 2024-10-01
- Reported currency
- GBP
- Companies House
- 12543677
- Evidence sources
- 2
2024-10-01Series B£80M / $105M
Resolved investor records
Sofinnova PartnersLead investorGilde HealthcareInvestorForbionInvestorBritish Patient CapitalInvestorSynconaInvestor
Investor links inherit this round’s named source and date. Resolved links use an exact canonical investor name; unresolved names remain unlinked.
Record fields
What the source states
Amounts, currency, stage and investor names are preserved as reported. No FX conversion, valuation inference or current-holding claim is added.
- Lead investors
- Sofinnova Partners
- Other investors
- Gilde Healthcare, Forbion, British Patient Capital, Syncona
- Source layers
- VC research snapshot, Live Chris T D1
- Snapshot
- 2026-08-15
Named evidence
Source trail
This page is published only when the record has a resolved company, disclosure date, round stage and at least one retained source URL.